Molecular Cancer Therapeutics strives to be the top choice for publishing the best science in the discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of approved therapeutics, mechanisms of drug action, mechanisms of drug resistance, biomarkers of drug response, novel models and technologies, and occasional drug toxicity mechanisms. While the Journal’s main focus is on small molecule and protein drugs, other molecular entities may be considered.

Molecular Cancer Therapeutics is abstracted and/or indexed in Current Contents/Clinical Medicine, MEDLINE, Science Citation Index, Scopus, and Web of Science.

Submission of Manuscripts
Online manuscript submission is welcomed at http://mct.msubmit.net. Before submitting a manuscript, please read the Instructions for Authors, which is available from the Journal’s home page at http://mct.aacrjournals.org.

Publication Charges
Beginning with manuscripts submitted January 1, 2016 or after, articles will be published with the understanding that the author(s) will pay both a publication fee plus a color figure handling fee. Please see the Instructions for Authors, which are available from the Journal’s home page at http://mct.aacrjournals.org.

Subscription Information
Nonmember Individuals
Subscriptions include print version with online access. Contacts listed below are for nonmember individual subscriptions.

USA and Rest of World (excluding Japan)
American Association for Cancer Research, 615 Chestnut Street, Philadelphia, PA 19106; 1-855-744-4667; pubsales@aacr.org

Japan
e-support@manusen.co.jp; journal@kinokuniya.co.jp; usaco@usaco.co.jp

International print subscriptions include cost of surface mail. Expedited mailing is available. Contact the American Association for Cancer Research for rates.